Central Pacific Bank Trust Division Increases Stock Holdings in Eli Lilly and Company $LLY

Central Pacific Bank Trust Division boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 25.8% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,990 shares of the company’s stock after acquiring an additional 1,843 shares during the period. Eli Lilly and Company accounts for about 0.8% of Central Pacific Bank Trust Division’s holdings, making the stock its 18th biggest position. Central Pacific Bank Trust Division’s holdings in Eli Lilly and Company were worth $6,859,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Wealth Preservation Advisors LLC bought a new position in shares of Eli Lilly and Company in the first quarter worth $27,000. Sumitomo Mitsui Financial Group Inc. purchased a new position in Eli Lilly and Company during the second quarter worth about $27,000. Evolution Wealth Management Inc. bought a new position in Eli Lilly and Company in the 2nd quarter worth about $29,000. Financial Gravity Companies Inc. purchased a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $31,000. Finally, Bare Financial Services Inc boosted its position in shares of Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company’s stock valued at $31,000 after acquiring an additional 29 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,062.67 on Tuesday. The company has a 50-day simple moving average of $943.82 and a two-hundred day simple moving average of $822.76. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The firm has a market cap of $1.00 trillion, a price-to-earnings ratio of 51.99, a PEG ratio of 1.14 and a beta of 0.37. The company has a quick ratio of 1.24, a current ratio of 1.55 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 109.52% and a net margin of 30.99%.The company’s quarterly revenue was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.18 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s payout ratio is currently 29.35%.

Analysts Set New Price Targets

LLY has been the topic of several research analyst reports. HSBC restated a “hold” rating and issued a $1,070.00 price objective on shares of Eli Lilly and Company in a research report on Wednesday, December 10th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Tuesday, October 14th. Guggenheim reaffirmed a “buy” rating and set a $1,163.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 3rd. Scotiabank assumed coverage on shares of Eli Lilly and Company in a research report on Thursday, November 13th. They issued a “sector outperform” rating and a $1,165.00 target price for the company. Finally, Sanford C. Bernstein increased their target price on Eli Lilly and Company from $1,100.00 to $1,300.00 and gave the company an “outperform” rating in a research note on Monday, November 24th. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $1,128.55.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.